Revance logo

Revance

Stock
Stock
Ticker: RVNC
RVNC

Price

Price

CHART BY

Frequently asked questions

Revance's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -1.923. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover Revance's stock, with a consensus target price of $6.60. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Revance reported a revenue of $247.00M.
Revance's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$159.93M. EBITDA measures the company's overall financial performance.
Revance has a free cash flow of -$194.91M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Revance employs approximately 597 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.

Financials

EPS (TTM) 
-1.923
Revenue (TTM) 
$247.00M
EBITDA (TTM) 
-$159.93M
Free Cashflow (TTM) 
-$194.91M

Analyst Ratings

The price target is $6.60 and the stock is covered by 1 analysts.

Buy

0

Hold

1

Sell

0

Information

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Employees
597
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
RVNC

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation